4.8 Article

Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression

期刊

CELL METABOLISM
卷 34, 期 3, 页码 441-+

出版社

CELL PRESS
DOI: 10.1016/j.cmet.2022.02.006

关键词

-

资金

  1. National Natural Science Foundation of China (NSFC) [32071145, 31771572]
  2. Natural Science Foundation of Jiangsu Province [BK20191356]
  3. Six Talent Peaks Project in Jiangsu Province [yy-014]
  4. Qin Lan Project of Jiangsu Province [KY520R202025]
  5. Key R&D Program of Jiangsu Province [BE2017708]
  6. NSFC Key Program [81730067, 82030067]
  7. NSFC International (Regional) Collaboration Program [82161160342]
  8. Major Project of NSFC [81991514]
  9. Jiangsu Provincial Key Medical Center Foundation
  10. Jiangsu Provincial Medical Outstanding Talent Foundation
  11. Jiangsu Provincial Medical Youth Talent Foundation
  12. Jiangsu Provincial Key Medical Talent Foundation
  13. Fundamental Research Funds for the Central Universities [14380493, 14380494]

向作者/读者索取更多资源

Hepatic osteodystrophy (HOD) is a metabolic bone disease associated with chronic liver disease. Upregulation of the phosphatase PP2Aca in the liver during HOD leads to downregulation of hepatokine lecithin-cholesterol acyltransferase (LCAT). Loss of LCAT function exacerbates bone loss in HOD mice. Cholesterol levels play a role in the regulation of osteoblast and osteoclast activities. LCAT improves liver function and reduces liver fibrosis in the HOD mouse model by promoting cholesterol transport from bone to liver.
Hepatic osteodystrophy (HOD) is a metabolic bone disease that is often associated with chronic liver disease and is marked by bone loss. Here, we demonstrate that hepatic expression of the phosphatase PP2Aca is upregulated during HOD, leading to the downregulation of expression of the hepatokine lecithin-cholesterol acyltransferase (LCAT). Loss of LCAT function markedly exacerbates the bone loss phenotype of HOD in mice. In addition, we found that alterations in cholesterol levels are involved in the regulation of osteoblast and osteoclast activities. We also found that LCAT improves liver function and relieves liver fibrosis in the mouse HOD model by promoting reversal of cholesterol transport from the bone to the liver. In summary, defects in a liver-bone axis occur during HOD that can be targeted to ameliorate disease progression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据